ALMS
Price
$11.10
Change
-$0.26 (-2.29%)
Updated
Sep 4 closing price
Capitalization
1.48B
66 days until earnings call
Intraday BUY SELL Signals
DRUG
Price
$65.16
Change
-$2.86 (-4.20%)
Updated
Sep 4 closing price
Capitalization
652.6M
Intraday BUY SELL Signals
Interact to see
Advertisement

ALMS vs DRUG

ALMS vs DRUG Comparison Chart in %
View a ticker or compare two or three
VS
ALMS vs. DRUG commentary
Sep 07, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALMS is a Buy and DRUG is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2026
Stock price -- (ALMS: $11.10 vs. DRUG: $65.16)
Brand notoriety: ALMS and DRUG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALMS: 152% vs. DRUG: 49%
Market capitalization -- ALMS: $1.48B vs. DRUG: $652.6M
ALMS [@Biotechnology] is valued at $1.48B. DRUG’s [@Biotechnology] market capitalization is $652.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALMS’s FA Score shows that 1 FA rating(s) are green whileDRUG’s FA Score has 1 green FA rating(s).

  • ALMS’s FA Score: 1 green, 4 red.
  • DRUG’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALMS and DRUG are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALMS’s TA Score shows that 4 TA indicator(s) are bullish while DRUG’s TA Score has 4 bullish TA indicator(s).

  • ALMS’s TA Score: 4 bullish, 5 bearish.
  • DRUG’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ALMS is a better buy in the short-term than DRUG.

Price Growth

ALMS (@Biotechnology) experienced а -50.40% price change this week, while DRUG (@Biotechnology) price change was -10.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.22%. For the same industry, the average monthly price growth was +5.23%, and the average quarterly price growth was +2396.59%.

Reported Earning Dates

ALMS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALMS($1.48B) has a higher market cap than DRUG($653M). ALMS YTD gains are higher at: 13.730 vs. DRUG (-16.504). DRUG has higher annual earnings (EBITDA): -39.25M vs. ALMS (-413.65M). ALMS has more cash in the bank: 502M vs. DRUG (308M). DRUG has less debt than ALMS: DRUG (65.6K) vs ALMS (36.4M). ALMS has higher revenues than DRUG: ALMS (7.4M) vs DRUG (0).
ALMSDRUGALMS / DRUG
Capitalization1.48B653M227%
EBITDA-413.65M-39.25M1,054%
Gain YTD13.730-16.504-83%
P/E Ratio0.17N/A-
Revenue7.4M0-
Total Cash502M308M163%
Total Debt36.4M65.6K55,488%
TECHNICAL ANALYSIS
Technical Analysis
ALMSDRUG
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
87%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 21 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ALMS
Daily Signal:
Gain/Loss:
DRUG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSLIX6.720.05
+0.75%
Transamerica Small Cap Value I
JSCVX27.32N/A
N/A
Janus Henderson Small Cap Value T
INDZX21.71-0.05
-0.23%
Columbia Intrinsic Value A
CUSUX21.03-0.08
-0.38%
Six Circles U.S. Unconstrained Equity
WPCSX42.08-0.29
-0.68%
AB Concentrated Growth C

ALMS and

Correlation & Price change

A.I.dvisor tells us that ALMS and ZNTL have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and ZNTL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
-2.29%
ZNTL - ALMS
33%
Poorly correlated
-2.92%
MRNA - ALMS
30%
Poorly correlated
-2.23%
VKTX - ALMS
27%
Poorly correlated
+2.62%
SNDX - ALMS
27%
Poorly correlated
-0.58%
DRUG - ALMS
27%
Poorly correlated
-4.20%
More